AMG-0101 is under clinical development by AnGes and currently in Phase I for Chronic Low Back Pain (CLBP). According to GlobalData, Phase I drugs for Chronic Low Back Pain (CLBP) have a 95% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AMG-0101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AMG-0101 overview

AMG-0101 (S-414114, NF-kB Decoy Oligodeoxynucleotide) is under development for the treatment of degenerative disc disease including discogenic lower back pain. It is administered through transdermal, injection and topical routes. NF-kB (nuclear factor-kappa B) is a transcription factor regulating the gene expression of molecules such as cytokines and adhesion factors related to immune response. Decoys belong to the nucleic-acid medicines. It was also under development for the treatment of atopic dermatitis as transdermal and topical formulation in Japan.

AnGes overview

AnGes is a biopharmaceutical company, which discovers and develops gene and nucleotide-based drugs and reagents for use in the functional analysis of genetic medications. The company specializes in the research and development (R&D) and practical application of genetic medicines. It has two major projects under development, namely, a hepatocyte growth factor (HGF) plasmid, which is a genetic medicine that improves blood circulation by regenerating blood vessels and NF-KB decoy oligonucleotide. The company also develops therapeutic vaccine projects including CIN (cervical intraepithelial neoplasia) therapeutic vaccines. It has operations in the US and Japan. AnGes is headquartered in Ibaraki, Osaka, Japan.

For a complete picture of AMG-0101’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.